Associated Papers
Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.
Hoste E et al.
Clinical Biochemistry, 2024
Novel Homozygous PADI6 Variants in Infertile Females with Early Embryonic Arrest.
Xu Y et al.
Frontiers in Cell and Developmental Biology, 2022
Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations.
Li X et al.
Pharmacogenomics and Personalized Medicine, 2021
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance.
Lee HH et al.
Molecular Cancer Therapeutics, 2015
Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC et al.
British Journal of Clinical Pharmacology, 2012
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Sissung TM et al.
Discovery Medicine, 2012
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.
Schwarz UI et al.
Pharmacogenetics and Genomics, 2011
Pharmacogenetic pathway analysis of docetaxel elimination.
Baker SD et al.
Clinical Pharmacology and Therapeutics, 2009
Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
Franke RM et al.
Clinical Pharmacology and Therapeutics, 2008
Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.
Meyer zu Schwabedissen HE et al.
Molecular Pharmaceutics, 0
Select a paper to view details